Biogen Inc (BIIB)

Jan 15, 2025, 9:20 AM EST - 2 days ago

Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)

Jan 14, 2025, 6:01 PM EST - 3 days ago

Biogen CEO sees no burning need for more acquisitions

Jan 13, 2025, 7:05 PM EST - 4 days ago

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Jan 13, 2025, 10:40 AM EST - 4 days ago

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

SAGE

Jan 13, 2025, 7:24 AM EST - 4 days ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

SAGE

Jan 10, 2025, 6:49 PM EST - 7 days ago

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

SAGE

Jan 10, 2025, 6:37 PM EST - 7 days ago

Biogen proposes to buy remaining stake in Sage in $442 million deal

Jan 8, 2025, 8:00 AM EST - 9 days ago

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

AGIO

Dec 30, 2024, 1:37 PM EST - 18 days ago

Beaten Down Biogen Stock Looks Attractive At Current Levels

Dec 27, 2024, 12:22 PM EST - 21 days ago

Investing pros think these stock-market losers are set to rebound in 2025

CE DG DLTR EL ENPH HUM INTC

Dec 23, 2024, 3:45 PM EST - 25 days ago

Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman

LLY VRTX

Dec 12, 2024, 12:52 PM EST - 5 weeks ago

Private Medicare plans must cover Biogen's ALS drug, US agency says

Dec 9, 2024, 1:44 PM EST - 5 weeks ago

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Dec 5, 2024, 8:30 AM EST - 6 weeks ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

PRAX STOK WGS

Dec 3, 2024, 12:15 PM EST - 6 weeks ago

Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript

Dec 3, 2024, 9:57 AM EST - 6 weeks ago

Biogen expects steady growth for Alzheimer's drug Leqembi in near term

Nov 20, 2024, 1:32 PM EST - 2 months ago

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

Nov 19, 2024, 1:00 AM EST - 2 months ago

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Nov 18, 2024, 1:18 PM EST - 2 months ago

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Nov 18, 2024, 7:00 AM EST - 2 months ago

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™

Nov 14, 2024, 1:53 PM EST - 2 months ago

5 Healthcare Stocks to Buy in a Beaten-Up Sector

AMGN LLY PFE XLV

Nov 14, 2024, 1:21 PM EST - 2 months ago

Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug

Nov 14, 2024, 11:17 AM EST - 2 months ago

EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen

Oct 31, 2024, 5:42 PM EDT - 2 months ago

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Oct 31, 2024, 1:28 PM EDT - 2 months ago

Biogen Analysts Slash Their Forecasts After Q3 Results

Oct 30, 2024, 7:30 PM EDT - 2 months ago

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference

Oct 30, 2024, 12:49 PM EDT - 2 months ago

Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:47 AM EDT - 2 months ago

Biogen's stock pops after earnings top estimates and company raises guidance

Oct 30, 2024, 6:54 AM EDT - 2 months ago

Biogen lifts annual profit forecast as cost cuts help

Oct 30, 2024, 6:50 AM EDT - 2 months ago

Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction

Oct 29, 2024, 6:00 PM EDT - 2 months ago

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases

Oct 28, 2024, 9:05 AM EDT - 2 months ago

Biogen appoints insider as CFO after Michael McDonnell to retire next year

Oct 26, 2024, 8:15 PM EDT - 2 months ago

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Oct 24, 2024, 7:30 AM EDT - 3 months ago

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

Oct 22, 2024, 7:30 AM EDT - 3 months ago

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

Oct 11, 2024, 3:34 PM EDT - 3 months ago

These 3 Stocks Are Screaming Oversold: Seize the Opportunity

MU REGN

Oct 9, 2024, 8:32 AM EDT - 3 months ago

Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment

Oct 9, 2024, 7:30 AM EDT - 3 months ago

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

Oct 8, 2024, 7:30 AM EDT - 3 months ago

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

Oct 6, 2024, 2:00 PM EDT - 3 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BLUE BMY CRSP EDIT EXAS NTLA

Sep 24, 2024, 7:18 AM EDT - 4 months ago

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Sep 24, 2024, 1:04 AM EDT - 4 months ago

Biogen-UCB's lupus drug meets main goal of late-stage trial

Sep 24, 2024, 1:00 AM EDT - 4 months ago

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Sep 20, 2024, 8:00 AM EDT - 4 months ago

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™

Sep 18, 2024, 3:36 PM EDT - 4 months ago

Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)

Sep 12, 2024, 4:36 PM EDT - 4 months ago

US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data

Sep 12, 2024, 3:32 PM EDT - 4 months ago

Healthcare Stocks Have Popped. Consider These 2 That Haven't.

LLY UNH XLV

Sep 12, 2024, 7:30 AM EDT - 4 months ago

Biogen Board Appoints Two New Independent Directors

Sep 11, 2024, 8:00 AM EDT - 4 months ago

Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE™ (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy